Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cardiome Pharma Corp (NASDAQ:CRME)

9.32
Delayed Data
As of Aug 04
 -0.06 / -0.64%
Today’s Change
5.84
Today|||52-Week Range
11.31
+0.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$157.3M

Company Description

Cardiome Pharma Corp. is a specialty pharmaceutical company, which engages in the discovery, development and commercialization of cardiovascular therapies that will improve the health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS, approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. The company was founded on December 12, 1986 and is headquartered in Vancouver, Canada.

Contact Information

Cardiome Pharma Corp.
1441 Creekside Drive
Vancouver British Columbia V6J 4S7
P:(604) 677-6905
Investor Relations:
16046776905311

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

William L. HunterPresident, Chief Executive Officer & Director
Sheila M. GrantChief Operating Officer
Jennifer ArchibaldChief Financial Officer
Steen Juul-MöllerMedical Director-Europe
Jürgen PolifkaGeneral Manager-European Sales & Marketing